Scinai Immunotherapeutics (SCNI) Current Deferred Revenue (2024 - 2025)

Generated on {Timestamp} © BusinessQuant.com

Generated on {Timestamp} Powered by

Scinai Immunotherapeutics (SCNI) has disclosed Current Deferred Revenue for 2 consecutive years, with $90000.0 as the latest value for Q4 2025.

• Quarterly Current Deferred Revenue fell 60.0% to $90000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $90000.0 through Dec 2025, down 60.0% year-over-year, with the annual reading at $90000.0 for FY2025, 60.0% down from the prior year.
• Current Deferred Revenue hit $90000.0 in Q4 2025 for Scinai Immunotherapeutics, down from $225000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $225000.0 in Q4 2024 to a low of $90000.0 in Q4 2025.

Peer Comparison